ASND on Nasdaq
Ascendis Pharma (Denmark)
Company in Copenhagen, Denmark.1
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with Evotec SE, Galápagos NV or Grifols, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from. Figures are in EUR, the currency the company reports in.
Key numbers, fiscal 2025
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Regions
United States brought in 75% of the revenue Ascendis Pharma (Denmark) broke down this way in fiscal 2025.
Regions by year
| Regions | 2023 | 2024 | 2025 |
|---|---|---|---|
| United States | 191.7M EUR | 233.1M EUR | 546.4M EUR |
| Europe | 869.0K EUR | 123.3M EUR | 120.9M EUR |
| Rest Of World | 74.2M EUR | 7.2M EUR | 52.8M EUR |
| Denmark | 0 EUR | 95.4M EUR | 12.9M EUR |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Other costs100¢720.1M EUR
Out of 720.1M EUR in revenue.3 The company lost money this year.
Where each dollar of operating cash went, fiscal 2025
- Kept or used elsewhere100¢53.9M EUR
Out of 53.9M EUR of cash from operations.3
Financial statements
No quarterly figures reported.
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Revenue | 720.1M EUR | 363.6M EUR | 266.7M EUR |
| Cost of sales | -94.9M EUR | -44.3M EUR | -44.4M EUR |
| Gross profit | 625.2M EUR | 319.4M EUR | 222.3M EUR |
| Research and development expenses | -303.6M EUR | -307.0M EUR | -413.5M EUR |
| Selling, general, and administrative expenses | -457.9M EUR | -291.1M EUR | -264.4M EUR |
| Operating profit/(loss) | -136.3M EUR | -278.8M EUR | -455.5M EUR |
| Share of profit/(loss) of associates | 16.3M EUR | -20.1M EUR | -18.4M EUR |
| Finance income | 114.0M EUR | 25.6M EUR | 43.9M EUR |
| Finance expenses | -206.7M EUR | -100.0M EUR | -44.1M EUR |
| Profit/(loss) before tax | -212.7M EUR | -373.2M EUR | -474.1M EUR |
| Income taxes (expenses) | -15.4M EUR | -4.8M EUR | -7.3M EUR |
| Net profit/(loss) for the year | -228.0M EUR | -378.1M EUR | -481.4M EUR |
| Attributable to owners of the Company | -228.0M EUR | -378.1M EUR | -481.4M EUR |
| Basic earnings/(loss) per share | -3.76 EUR | -6.53 EUR | -8.55 EUR |
| Diluted earnings/(loss) per share | -3.76 EUR | -6.53 EUR | -8.55 EUR |
| Exchange differences on translating foreign operations | -3.5M EUR | 1.1M EUR | -2.7M EUR |
| Other comprehensive income/(loss) for the year, net of tax | -3.5M EUR | 1.1M EUR | -2.7M EUR |
| Total comprehensive income/(loss) | -231.6M EUR | -377.0M EUR | -484.2M EUR |
| Attributable to owners of the Company | -231.6M EUR | -377.0M EUR | -484.2M EUR |
No quarterly figures reported.
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Intangible assets | 3.7M EUR | 4.0M EUR | |
| Property, plant and equipment | 146.5M EUR | 98.7M EUR | |
| Investments in associates | 32.5M EUR | 13.6M EUR | |
| Other receivables | 10.9M EUR | 2.3M EUR | |
| Total non-current assets | 193.6M EUR | 118.6M EUR | |
| Inventories | 301.5M EUR | 295.6M EUR | |
| Trade receivables | 141.3M EUR | 166.3M EUR | |
| Income tax receivables | 1.8M EUR | 1.8M EUR | |
| Other receivables | 14.6M EUR | 9.4M EUR | |
| Prepayments | 33.7M EUR | 28.3M EUR | |
| Cash and cash equivalents | 616.0M EUR | 559.5M EUR | 392.2M EUR |
| Total current assets | 1.1B EUR | 1.1B EUR | |
| Total assets | 1.3B EUR | 1.2B EUR | |
| Share capital | 8.3M EUR | 8.1M EUR | |
| Distributable equity | -171.1M EUR | -113.9M EUR | |
| Total equity | -162.8M EUR | -105.7M EUR | -145.7M EUR |
| Borrowings | 385.3M EUR | 365.1M EUR | |
| Contract liabilities | 1.1M EUR | 5.0M EUR | |
| Deferred tax liabilities | 9.6M EUR | 7.3M EUR | |
| Total non-current liabilities | 396.0M EUR | 377.3M EUR | |
| Borrowings | 429.4M EUR | 458.2M EUR | |
| Derivative liabilities | 256.2M EUR | 150.7M EUR | |
| Convertible notes current | 685.6M EUR | 608.9M EUR | |
| Borrowings | 57.1M EUR | 33.3M EUR | |
| Contract liabilities | 4.9M EUR | 936.0K EUR | |
| Trade payables and accrued expenses | 90.7M EUR | 96.4M EUR | |
| Other liabilities | 58.2M EUR | 68.0M EUR | |
| Income tax payables | 6.4M EUR | 1.2M EUR | |
| Provisions | 166.4M EUR | 99.1M EUR | |
| Other current liabilities | 383.8M EUR | 299.0M EUR | |
| Total current liabilities | 1.1B EUR | 907.9M EUR | |
| Total liabilities | 1.5B EUR | 1.3B EUR | |
| Total equity and liabilities | 1.3B EUR | 1.2B EUR |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net profit/(loss) for the year | -228.0M EUR | -378.1M EUR | -481.4M EUR |
| Reversal of finance income | -114.0M EUR | -25.6M EUR | -43.9M EUR |
| Reversal of finance expenses | 206.7M EUR | 100.0M EUR | 44.1M EUR |
| Reversal of (gain)/loss on disposal of property, plant and equipment | 0 EUR | -91.0K EUR | 5.0K EUR |
| Reversal of income taxes | 15.4M EUR | 4.8M EUR | 7.3M EUR |
| Non-cash consideration relating to revenue | -5.6M EUR | -27.1M EUR | -2.4M EUR |
| Share of (profit)/loss of associates | -16.3M EUR | 20.1M EUR | 18.4M EUR |
| Share-based payment | 116.2M EUR | 95.5M EUR | 66.7M EUR |
| Depreciation | 17.2M EUR | 17.2M EUR | 18.4M EUR |
| Impairment of property, plant and equipment | 5.3M EUR | 0 EUR | 7.8M EUR |
| Amortization | 490.0K EUR | 467.0K EUR | 483.0K EUR |
| Inventories | -5.9M EUR | -86.7M EUR | -78.3M EUR |
| Receivables | 15.6M EUR | -118.6M EUR | -32.8M EUR |
| Prepayments | -6.1M EUR | 10.4M EUR | -11.4M EUR |
| Contract liabilities | 131.0K EUR | -1.2M EUR | -7.1M EUR |
| Trade payables, accrued expenses and other liabilities | -10.4M EUR | 27.0M EUR | 3.6M EUR |
| Provisions | 77.6M EUR | 62.0M EUR | 26.2M EUR |
| Cash flows generated from/(used in) operations | 68.2M EUR | -299.9M EUR | -464.3M EUR |
| Finance income received | 15.3M EUR | 14.4M EUR | 17.0M EUR |
| Finance expenses paid | -22.9M EUR | -15.2M EUR | -15.7M EUR |
| Income taxes received/(paid) | -6.7M EUR | -5.5M EUR | -4.5M EUR |
| Cash flows from/(used in) operating activities | 53.9M EUR | -306.2M EUR | -467.4M EUR |
| Proceeds from disposal of property, plant and equipment | 0 EUR | 950.0K EUR | 51.0K EUR |
| Acquisition of intangible assets and property, plant and equipment | -8.5M EUR | -1.4M EUR | -2.4M EUR |
| Settlement of marketable securities | 0 EUR | 7.4M EUR | 288.9M EUR |
| Cash flows from/(used in) investing activities | -8.5M EUR | 6.9M EUR | 286.5M EUR |
| Repayment of borrowings | -22.0M EUR | -11.4M EUR | -10.4M EUR |
| Net proceeds from borrowings | 0 EUR | 134.2M EUR | 136.3M EUR |
| Proceeds from exercise of warrants | 87.1M EUR | 30.5M EUR | 10.3M EUR |
| Proceeds from follow-on public offering | 0 EUR | 309.9M EUR | 0 EUR |
| Costs of follow-on public offering | 0 EUR | -19.3M EUR | 0 EUR |
| Acquisitions of treasury shares, net of transactions costs | -17.4M EUR | 0 EUR | 0 EUR |
| Payment of withholding taxes under stock incentive programs | -11.4M EUR | 0 EUR | -1.8M EUR |
| Cash flows from/(used in) financing activities | 36.3M EUR | 443.9M EUR | 134.3M EUR |
| Increase/(decrease) in cash and cash equivalents | 81.7M EUR | 144.6M EUR | -46.6M EUR |
| Effect of exchange rate changes on balances held in foreign currencies | -25.2M EUR | 22.8M EUR | -6.0M EUR |
Timeline
- 2007Founded Founded1
Recent filings
- Oct 14, 20266-K
- Sep 29, 20266-K
- Sep 28, 20264
- Sep 15, 20266-K
- Sep 15, 20266-K
- Sep 9, 20266-K
- Sep 9, 20264
- Sep 9, 20266-K
- Sep 8, 2026144
- Sep 3, 20264
- Sep 2, 2026144
- Aug 31, 20266-K
- Aug 18, 20264
- Aug 13, 20266-K
- Aug 13, 20266-K
Every filing from the last three years, summarized. The full record is on SEC EDGAR.2
Links
- WikidataQ104479983
- SEC EDGARCIK 1612042
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10